|
Sep 28, 2023
|
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
- Translarna CHMP opinion re-examination request to be submitted - SOUTH PLAINFIELD, N.J. , Sept. 28, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today further strategic prioritization and associated workforce reduction. The portfolio prioritization continues the process
|
|
|
Sep 15, 2023
|
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
- Conference call to be held at 8: 45 am EDT - SOUTH PLAINFIELD, N.J. , Sept. 15, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative opinion on the
|
|
|
Sep 07, 2023
|
PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
- 2023 recipients include patient advocacy organizations in Australia and Brazil - SOUTH PLAINFIELD, N.J. , Sept. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the two recipients of its 2023 STRIVE Awards for Duchenne Muscular Dystrophy.
|
|
|
Aug 30, 2023
|
PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , Aug. 30, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Citi 2023 18 th Annual BioPharma Conference Wednesday, Sept. 6 , at 9:40 a.m.
|
|
|
Aug 28, 2023
|
PTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
- Results from the APHENITY trial in PKU and long-term extension study including Phe tolerance to be highlighted - SOUTH PLAINFIELD, N.J. , Aug. 28, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from the APHENITY clinical trial and long-term extension study
|
|
|
Aug 03, 2023
|
PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
– Second-quarter 2023 total revenue of $214 million , representing 29% year-over-year growth – – Positive APHENITY and PIVOT-HD data readouts in the second quarter – – Numerous regulatory milestones planned for the second half of 2023 – SOUTH PLAINFIELD, N.J. , Aug.
|
|
|
Jul 21, 2023
|
CHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy
- Following ratification by the European Commission , Evrysdi will be available to treat all spinal muscular atrophy patients, including babies from birth - SOUTH PLAINFIELD, N.J. , July 21, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal
|
|
|
Jul 20, 2023
|
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results
SOUTH PLAINFIELD, N.J. , July 20, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, Aug.
|
|
|
Jul 19, 2023
|
PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize
-- Dr. Jacobson recognized for his pioneering work in nonsense-mediated mRNA decay -- SOUTH PLAINFIELD, N.J. , July 19, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Allan Jacobson , Ph.D., co-founder of PTC and member of the Board of Directors, was presented the
|
|
|
Jul 18, 2023
|
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , July 18, 2023 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on July 13, 2023 , the company approved non-statutory stock options to purchase an aggregate of 66,380 shares of its common stock and 30,685 restricted stock units ("RSUs"), each
|
|
